Xiaoyu Hong - Nanjing Geneseeq Technology Inc

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Revealing Underlying Regulatory Mechanisms of LINC00313 in Osimertinib-resistant LUAD Cells by Cerna Network Analysis

Dandan Ding, Chenguang Xu, Jufeng Zhang,Ying Zhang, Lipeng Xue,Jingjing Song,Zhiming Luo,Xiaoyu Hong,Jian Wang,Weicheng Liang,Xingyang Xue

TRANSLATIONAL ONCOLOGY (2024)

引用0浏览0WOS引用

Neoadjuvant Chemo-Immunotherapy with Camrelizumab Plus Nab-Paclitaxel and Cisplatin in Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Pilot Phase II Trial

Di Wu,Yong Li,Pengfei Xu, Qi Fang,Fei Cao,Hongsheng Lin,Yin Li, Yong Su,Lixia Lu,Lei Chen,Yizhuo Li, Zheng zhao,Xiaoyu Hong, Guohong Li, Yaru Tian, Jinyun Sun,Honghong Yan,Yunyun Fan,Xinrui Zhang,Zhiming Li,Xuekui Liu

NATURE COMMUNICATIONSno. 1 (2024)

引用0浏览0WOSNATURE引用

A Pilot Phase II Trial of Neoadjuvant Camrelizumab Plus Nab-Paclitaxel and Cisplatin (neocpc) for Locoregionally Advanced, Resectable Squamous Cell Carcinoma of the Head and Neck

Di Wu,Yong Li,Peng-Fei Xu,Xinrui Zhang,Hongsheng Lin,Yin Li, Qi Fang,Fei Cao,Yong Su,Li-Xia Lu,Yizhuo Li, Zheng Zhao,Xiaoyu Hong, Guohong Li,Honghong Yan,Yunyun Fan,Lei Chen,Zhiming Li,Xuekui Liu

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023)

引用0浏览0引用

High tumor copy number variations burden was associated with poor prognosis in patients with endocrine-resistant breast cancer

Qianyi Lu,Kuikui Jiang, Na Wang,Jiaping Li,Ping Zhang,Ruoxi Hong,Xiaoyu Hong,Yang Shao,Jingmin Zhang,Shusen Wang,Fei Xu

Research Square (Research Square) (2023)

引用0浏览0引用

The Profiling of Circulating Tumor DNA Liquid Biopsy in Children and Adolescent Lymphoblastic Lymphoma

Juan Wang,Yanlai Tang,Tang Wen,Haixia Guo,Xiuli Yuan,Aiguo Liu,Xiaohong Zhang,Lihua Yang,Yanpeng Wu,Xin Tian,Hao Xiong,Pan Wu,Xiangling He, Qiaohua Zhang,M. James You,Xiaoyu Hong, Gege Huang,Zijun Zhen,Jia Zhu,Suying Lu, Feifei Sun,Junting Huang,Yizhuo Zhang

Blood（2022）

引用0浏览0引用

NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report

Huilin Wang,Qitao Yu,Lina Shi,Qinhan Hou,Liang Dan,Chuqiao Liang,Xiaoyu Hong,Yun Zhao,Ruiling Ning

FRONTIERS IN ONCOLOGY（2022）

引用0浏览0WOS引用

Diagnostic Value of Genetic Mutation Analysis and Mutation Profiling of Cell-Free DNA in Intraocular Fluid for Vitreoretinal Lymphoma

Xiaoqing Chen,Yunwei Hu,Wenru Su,Shizhao Yang, Xiaoxiao Wang,Ping Zhang,Xiaoyu Hong,Chuqiao Liang,Zhuyun Qian,Ziqiang Li,Yong Tao,Huiqiang Huang,Dan Liang

CANCER COMMUNICATIONS（2022）

引用3浏览0引用

THE PROFILING OF CIRCULATING TUMOR DNA IN PEDIATRIC MATURE B-CELL NON-HODGKIN LYMPHOMA (B-NHL): A MULTICENTER, PROSPECTIVE CLINICAL STUDY

Juan Wang, Haixia Guo,Cai Yun, Huiqin Chen,Liangchun Yang, Huihong Dou, Xin Tian, Hao Xiong,M. James You,Xiaoyu Hong,Chuqiao Liang,Zijun Zhen, Jia Zhu,Suying Lu,Feifei Sun,Junting Huang,Yizhuo Zhang

Blood（2021）

引用0浏览0引用

Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review

Yanchun Qu,Yufeng Liu,Kailin Ding, Yong Li,Xiaoyu Hong,Haibo Zhang

OncoTargets and therapy（2021）

引用2浏览0WOS引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn